Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07540897 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
A Phase 3 study, sponsored by Alkermes.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07540897: Recruiting Phase 3 study, sponsored by Alkermes.
NCT07540897 is a Phase 3 study that is actively recruiting participants, run by Alkermes. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07540897, a Phase 3 study, is actively recruiting participants, sponsored by Alkermes.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Interventions
- DRUG Placebo
- DRUG ALKS 2680 Dose 1
- DRUG ALKS 2680 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What NCT07540897 shows while recruiting
NCT07540897 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07540897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07540897 about?
NCT07540897 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)". The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
What is the current status of trial NCT07540897?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07540897?
The interventions under investigation include: Placebo (DRUG), ALKS 2680 Dose 1 (DRUG), ALKS 2680 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07540897?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07540897's enrollment target sits among peer trials
150 1519th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia